dalteparin has been researched along with Innate Inflammatory Response in 34 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In non-ST-elevation acute coronary syndrome, there was a simultaneous activation of the inflammation, coagulation, and fibrinolysis systems, despite aspirin and dalteparin treatment." | 9.11 | Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. ( Armstrong, P; Barnathan, E; Califf, R; James, SK; Siegbahn, A; Simoons, ML; Wallentin, L, 2004) |
| "The study is a prospective single centre open-label trial of patients with high-risk acute coronary syndrome treated with percutaneous intervention (PCI) who were randomized to anticoagulation with UFH or enoxaparin with HD-tirofiban (25 microg kg(-1) bolus)." | 5.14 | High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention. ( Aroney, CN; Bett, JH; Perrin, EJ; Ray, MJ; Walters, DL; Wood, P, 2010) |
| "The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when administered with indirect thrombin inhibition as compared with monotherapy with direct thrombin inhibition with bivalirudin among patients with non-ST-segment elevation acute coronary syndromes (ACS)." | 5.12 | A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. ( Braunwald, E; Bulle, T; Cohen, DJ; Fish, P; Gibson, CM; Jennings, LK; Kovach, R; Lakkis, N; Lui, HH; McCabe, CH; Morrow, DA; Murphy, SA; Palabrica, TM; Stone, PH, 2006) |
| "In non-ST-elevation acute coronary syndrome, there was a simultaneous activation of the inflammation, coagulation, and fibrinolysis systems, despite aspirin and dalteparin treatment." | 5.11 | Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. ( Armstrong, P; Barnathan, E; Califf, R; James, SK; Siegbahn, A; Simoons, ML; Wallentin, L, 2004) |
| "Studies reporting vein re-opening, inflammation expressed as Gadolinium enhancement and coagulation parameters were searched in the literature and pooled into a meta-analysis using an inverse variance with random effects." | 4.86 | P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. ( Deatrick, KB; Henke, PK; Londy, FJ; Myers, DD; Ramacciotti, E; Rectenwald, JE; Schaub, RG; Wakefield, TW; Wrobleski, SK, 2010) |
| "Histopathological examination of the enoxaparin and rivaroxaban groups revealed that the skin was mostly normal or intact with minimal inflammation." | 3.80 | Effects of enoxaparin and rivaroxaban on tissue survival in skin degloving injury: an experimental study. ( Alabalik, U; Alemdar, C; Azboy, I; Bulut, M; Demirtaş, A; Uçar, Y, 2014) |
| "We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation." | 3.74 | Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. ( Dragomanovits, S; Kalogeropoulos, AS; Kremastinos, DT; Papathanasiou, S; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2007) |
| "In women with a history of recurrent miscarriage, the risk of miscarriage in a subsequent pregnancy is about 30% to 40%." | 2.74 | Use of heparin in women with early and late miscarriages with and without thrombophilia. ( Baumgarten, S; Dörner, T; Kadecki, O; Kiesewetter, H; Monien, S; Salama, A, 2009) |
| "Patients with end-stage renal disease (ESRD) suffer from high mortality rates of cardiovascular diseases, conditions closely linked to the magnitude of their chronic low-grade inflammation." | 2.71 | Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. ( Gram, J; Jespersen, J; Pedersen, RS; Sjøland, JA, 2005) |
| " Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID-19 ICU patients is unknown." | 1.91 | Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. ( Endeman, H; Hunfeld, NGM; Kruip, MJHA; Preijers, T; Romano, LGR, 2023) |
| "Infective endocarditis is associated with significant morbidity and mortality, despite advances in diagnosis and treatment strategies." | 1.51 | No Fever, No Murmur, No Problem? A Concealed Case of Infective Endocarditis. ( Gorman, M; McCann, M; McKeown, B, 2019) |
| "Atherosclerosis is characterized by a proliferation of vascular smooth muscle cells (VSMCs) and their migration to the intima, which induces thickening of the intima itself, but the mechanism remains poorly understood." | 1.43 | Role of parnaparin in atherosclerosis. ( Artico, M; Bonomini, F; Parnigotto, P; Rezzani, R; Rodella, LF; Taurone, S; Zamai, L, 2016) |
| "Histological examination of untreated colitis mice showed a massive loss of crypt architecture and goblet cells, infiltration of immune cells and the presence of edema, while all aspects of this pathology were alleviated by oral enoxaparin." | 1.42 | Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory Responses. ( Eri, RD; Gueven, N; Lean, QY; Patel, RP; Peterson, GM; Randall-Demllo, S; Sohal, SS; Stewart, N, 2015) |
| "DSS colitis was induced in Sdc1-deficient (knockout (KO)) and wild-type mice by oral administration of 3% DSS." | 1.36 | Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. ( Domschke, W; Floer, M; Gassar, ES; Götte, M; Heidemann, J; Kiesel, L; Kucharzik, T; Luegering, A; Wild, MK, 2010) |
| "Since low molecular weight heparin has greater bioavailability and sustained serum levels in vivo than unfractionated heparin, it has been used to supplant unfractionated heparin to achieve therapeutic anticoagulation in humans." | 1.35 | Enoxaparin does not ameliorate limb ischemia-reperfusion injury. ( Abbruzzese, TA; Albadawi, H; Kang, J; Lamuraglia, GM; Patel, VI; Watkins, MT; Yoo, JH, 2008) |
| "Pretreatment with indomethacin completely reversed both of the therapeutic effects of dalteparin, whereas pretreatment with NS-398, a selective inhibitor of cyclooxygenase-2, did not." | 1.33 | Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats. ( Harada, N; Okajima, K; Uchiba, M, 2006) |
| " This study evaluates the dose-response relationship using a selectin receptor antagonist." | 1.31 | P-selectin antagonism causes dose-dependent venous thrombosis inhibition. ( Chapman, AM; Fex, BA; Greenfield, LJ; Londy, FJ; Myers, DD; Schaub, R; Wakefield, TW; Wrobleski, SK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (44.12) | 29.6817 |
| 2010's | 15 (44.12) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Romano, LGR | 2 |
| Hunfeld, NGM | 2 |
| Kruip, MJHA | 2 |
| Endeman, H | 2 |
| Preijers, T | 2 |
| Bielecki, M | 1 |
| Karpik, M | 1 |
| Skowroński, J | 1 |
| Bonomini, F | 1 |
| Taurone, S | 1 |
| Parnigotto, P | 1 |
| Zamai, L | 1 |
| Rodella, LF | 1 |
| Artico, M | 2 |
| Rezzani, R | 1 |
| Riganò, R | 1 |
| Buttari, B | 1 |
| Profumo, E | 1 |
| Ionta, B | 1 |
| Bosco, S | 1 |
| Rasile, M | 1 |
| Bianchi, E | 1 |
| Bruno, M | 1 |
| Fumagalli, L | 1 |
| Faour, WH | 1 |
| Choaib, A | 1 |
| Issa, E | 1 |
| Choueiry, FE | 1 |
| Shbaklo, K | 1 |
| Alhajj, M | 1 |
| Sawaya, RT | 1 |
| Harhous, Z | 1 |
| Alefishat, E | 1 |
| Nader, M | 1 |
| Berkowitz, S | 1 |
| Gofrit, SG | 1 |
| Aharoni, SA | 1 |
| Golderman, V | 1 |
| Qassim, L | 1 |
| Goldberg, Z | 1 |
| Dori, A | 1 |
| Maggio, N | 1 |
| Chapman, J | 1 |
| Shavit-Stein, E | 1 |
| Spiegelburg, DT | 1 |
| Mannes, M | 1 |
| Schultze, A | 1 |
| Scheibenberger, F | 1 |
| Müller, F | 1 |
| Klitzing, A | 1 |
| Messerer, DAC | 1 |
| Nilsson Ekdahl, K | 1 |
| Nilsson, B | 1 |
| Huber-Lang, M | 1 |
| Braun, CK | 1 |
| Shaker, RA | 1 |
| Abboud, SH | 1 |
| Assad, HC | 1 |
| Hadi, N | 1 |
| Vicci, H | 1 |
| Eblen-Zajjur, A | 1 |
| López, M | 1 |
| Crespo, G | 1 |
| Navarro, M | 1 |
| McCann, M | 1 |
| Gorman, M | 1 |
| McKeown, B | 1 |
| Ilhan, O | 1 |
| Ilhan, N | 1 |
| Coşkun, M | 1 |
| Dağlioğlu, MC | 1 |
| Ayhan Tuzcu, E | 1 |
| Ayintap, E | 1 |
| Keskın, U | 1 |
| Oksüz, H | 1 |
| Azboy, I | 1 |
| Demirtaş, A | 1 |
| Bulut, M | 1 |
| Alabalik, U | 1 |
| Uçar, Y | 1 |
| Alemdar, C | 1 |
| Gysler, SM | 1 |
| Mulla, MJ | 1 |
| Stuhlman, M | 1 |
| Sfakianaki, AK | 1 |
| Paidas, MJ | 1 |
| Stanwood, NL | 1 |
| Gariepy, A | 1 |
| Brosens, JJ | 1 |
| Chamley, LW | 1 |
| Abrahams, VM | 1 |
| Lean, QY | 1 |
| Eri, RD | 1 |
| Randall-Demllo, S | 1 |
| Sohal, SS | 1 |
| Stewart, N | 1 |
| Peterson, GM | 1 |
| Gueven, N | 1 |
| Patel, RP | 1 |
| Ozkececi, ZT | 1 |
| Gonul, Y | 1 |
| Karavelioglu, A | 1 |
| Bozkurt, MF | 1 |
| Kacar, E | 1 |
| Bal, A | 1 |
| Ozsoy, M | 1 |
| Turamanlar, O | 1 |
| Celep, B | 1 |
| Ramacciotti, E | 1 |
| Myers, DD | 3 |
| Wrobleski, SK | 3 |
| Deatrick, KB | 1 |
| Londy, FJ | 3 |
| Rectenwald, JE | 1 |
| Henke, PK | 1 |
| Schaub, RG | 3 |
| Wakefield, TW | 3 |
| Floer, M | 1 |
| Götte, M | 1 |
| Wild, MK | 1 |
| Heidemann, J | 1 |
| Gassar, ES | 1 |
| Domschke, W | 1 |
| Kiesel, L | 1 |
| Luegering, A | 1 |
| Kucharzik, T | 1 |
| Walters, DL | 1 |
| Ray, MJ | 1 |
| Wood, P | 1 |
| Perrin, EJ | 1 |
| Bett, JH | 1 |
| Aroney, CN | 1 |
| Uzan, A | 1 |
| Welsh, RC | 1 |
| Armstrong, PW | 1 |
| Rumelt, S | 1 |
| Stolovich, C | 1 |
| Segal, ZI | 1 |
| Rehany, U | 1 |
| Wilson, ME | 1 |
| Trivedi, RH | 1 |
| Gibson, CM | 1 |
| Morrow, DA | 1 |
| Murphy, SA | 1 |
| Palabrica, TM | 1 |
| Jennings, LK | 1 |
| Stone, PH | 1 |
| Lui, HH | 1 |
| Bulle, T | 1 |
| Lakkis, N | 1 |
| Kovach, R | 1 |
| Cohen, DJ | 1 |
| Fish, P | 1 |
| McCabe, CH | 1 |
| Braunwald, E | 1 |
| Rizos, I | 1 |
| Tsiodras, S | 1 |
| Rigopoulos, AG | 1 |
| Dragomanovits, S | 1 |
| Kalogeropoulos, AS | 1 |
| Papathanasiou, S | 1 |
| Sakadakis, EA | 1 |
| Kremastinos, DT | 1 |
| Meier, TR | 2 |
| Zajkowski, PJ | 1 |
| Hawley, AE | 1 |
| Bedard, PW | 1 |
| Ballard, NE | 1 |
| Kaila, N | 1 |
| Vlasuk, GP | 1 |
| Baxi, S | 1 |
| Crandall, DL | 1 |
| Wrobleski, S | 1 |
| Hawley, A | 1 |
| Farris, D | 1 |
| Elokdah, H | 1 |
| Sigler, R | 1 |
| Wakefield, T | 1 |
| Myers, D | 1 |
| Abbruzzese, TA | 1 |
| Albadawi, H | 1 |
| Kang, J | 1 |
| Patel, VI | 1 |
| Yoo, JH | 1 |
| Lamuraglia, GM | 1 |
| Watkins, MT | 1 |
| Wat, JM | 1 |
| Hawrylyshyn, K | 1 |
| Baczyk, D | 1 |
| Greig, IR | 1 |
| Kingdom, JC | 1 |
| Monien, S | 1 |
| Kadecki, O | 1 |
| Baumgarten, S | 1 |
| Salama, A | 1 |
| Dörner, T | 1 |
| Kiesewetter, H | 1 |
| James, SK | 1 |
| Siegbahn, A | 1 |
| Armstrong, P | 1 |
| Barnathan, E | 1 |
| Califf, R | 1 |
| Simoons, ML | 1 |
| Wallentin, L | 1 |
| Harada, N | 1 |
| Okajima, K | 1 |
| Uchiba, M | 1 |
| Schaub, R | 1 |
| Fex, BA | 1 |
| Chapman, AM | 1 |
| Greenfield, LJ | 1 |
| O'Flynn, AM | 1 |
| Watts, M | 1 |
| Wall, D | 1 |
| Molefe, C | 1 |
| O'Keeffe, D | 1 |
| Finucane, P | 1 |
| Sjøland, JA | 1 |
| Pedersen, RS | 1 |
| Jespersen, J | 1 |
| Gram, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis[NCT02506985] | Phase 4 | 10 participants (Actual) | Interventional | 2015-07-31 | Terminated | ||
| Randomized Clinical Trial Evaluating Anti-inflammatory Effect of Low Molecular-Weight Heparin in Pediatric Cataract and Intraocular Lens Surgery[NCT00986076] | Phase 4 | 23 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for dalteparin and Innate Inflammatory Response
| Article | Year |
|---|---|
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies.
Topics: Acute Kidney Injury; Aldosterone; Angiotensins; Antibodies, Monoclonal, Humanized; Autopsy; Biopsy; | 2022 |
P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.
Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Enoxaparin; Fibrin Fibrinogen | 2010 |
[Thrombosis and ischemia: experimental data].
Topics: Animals; Apoptosis; Coronary Thrombosis; Disease Models, Animal; Dogs; Enoxaparin; Fibrinolytic Agen | 2002 |
A marriage of enhancement: fibrinolysis and conjunctive therapy.
Topics: Animals; Antithrombins; Aspirin; Blood Platelets; Cell Adhesion; Clinical Trials as Topic; Dose-Resp | 2004 |
6 trials available for dalteparin and Innate Inflammatory Response
| Article | Year |
|---|---|
The effect of enoxaparin-containing irrigation fluid used during cataract surgery on postoperative inflammation in patients with diabetes.
Topics: Aged; Anterior Chamber; Anticoagulants; Cataract; Cataract Extraction; Diabetes Mellitus; Diabetic R | 2013 |
High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Biomarkers; Blood Coagulation F | 2010 |
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Drug Therapy, Combin | 2006 |
Use of heparin in women with early and late miscarriages with and without thrombophilia.
Topics: Abortion, Habitual; Adult; Age Factors; Aspirin; Biomarkers; Case-Control Studies; Dalteparin; Drug | 2009 |
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
Topics: Abciximab; Aged; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Blood Coagula | 2004 |
Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients.
Topics: Adult; Aged; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Female; Fibrin; Fibrin Fib | 2005 |
24 other studies available for dalteparin and Innate Inflammatory Response
| Article | Year |
|---|---|
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
The effect of prophylactic doses of nadroparin and therapeutic doses of betamethasone on skin flap survival in rats.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Betamethasone; Graft Survival; Inflammation; Male | 2009 |
Role of parnaparin in atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Proliferation; Disease Models, Animal; Heparin, Lo | 2016 |
Protective role of parnaparin in reducing systemic inflammation and atherosclerotic plaque formation in ApoE-/- mice.
Topics: Animals; Apolipoproteins E; Arteries; Disease Models, Animal; Fatty Liver; Fibrinolytic Agents; Gene | 2011 |
LPS-Induced Coagulation and Neuronal Damage in a Mice Model Is Attenuated by Enoxaparin.
Topics: Animals; Disease Models, Animal; Enoxaparin; Inflammation; Lipopolysaccharides; Mice; Mice, Inbred C | 2022 |
Impact of surface coating and systemic anticoagulants on hemostasis and inflammation in a human whole blood model.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemostasis; Heparin; Humans; Inflammation | 2023 |
Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiotonic Agents; Cardiotoxicity; Doxorubicin; En | 2018 |
Enoxaparin pretreatment effect on local and systemic inflammation biomarkers in the animal burn model.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antithrombin III; Biomarkers; Burns; C-Reactive P | 2019 |
No Fever, No Murmur, No Problem? A Concealed Case of Infective Endocarditis.
Topics: Adult; Amphetamine; Analgesics, Opioid; Anti-Bacterial Agents; C-Reactive Protein; Endocarditis; Eno | 2019 |
Effects of enoxaparin and rivaroxaban on tissue survival in skin degloving injury: an experimental study.
Topics: Animals; Disease Models, Animal; Enoxaparin; Fibrinolytic Agents; Inflammation; Male; Morpholines; N | 2014 |
Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Calcitriol; Cell Line; Cytokines; D | 2015 |
Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory Responses.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Anticoagulants; Colitis; Cytokines; Dextran Sulfat | 2015 |
The effect of enoxaparin on seroma and mesh-tissue adhesion in a hernia model.
Topics: Animals; Disease Models, Animal; Enoxaparin; Hernia; Inflammation; Male; Polypropylenes; Rats; Rats, | 2016 |
Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.
Topics: Animals; Caco-2 Cells; Cell Adhesion; Cell Proliferation; Colitis; Dextran Sulfate; Enoxaparin; Fibr | 2010 |
Intraoperative enoxaparin minimizes inflammatory reaction after pediatric cataract surgery.
Topics: Acetates; Cataract; Cataract Extraction; Cell Count; Drug Combinations; Endothelium, Corneal; Enoxap | 2006 |
Low molecular-weight heparin in the intraocular irrigating solution in pediatric cataract and intraocular lens surgery.
Topics: Acetates; Cataract; Cataract Extraction; Drug Combinations; Endothelium, Corneal; Enoxaparin; Fibrin | 2006 |
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein | 2007 |
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Blood Platelets; Disease Models, A | 2008 |
Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxaparin; Fibrosis; Indoleaceti | 2008 |
Enoxaparin does not ameliorate limb ischemia-reperfusion injury.
Topics: Animals; Anticoagulants; Biomarkers; Enoxaparin; Hindlimb; Inflammation; Male; Mice; Mice, Inbred C5 | 2008 |
Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cell Adhesion; Complement Activation; Dalte | 2018 |
Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticoagulants; Calcium; Cyclooxygenase 2 Inhibitors; Daltepa | 2006 |
P-selectin antagonism causes dose-dependent venous thrombosis inhibition.
Topics: Animals; Anticoagulants; Balloon Occlusion; Dalteparin; Disease Models, Animal; Dose-Response Relati | 2001 |
Inflammatory bowel disease and thromboembolism. Is inflammation at the centre of the clot?
Topics: Adult; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Inflammation; Inflammatory Bow | 2013 |